- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approval September 28, 2023).
- Why 4/10
- Pombiliti is already FDA-approved and commercializing with no pending regulatory decision or pivotal readout in the next 12 months. It is one of several products in BioMarin's diversified rare-disease portfolio (alongside Voxzogo and Galafold), so its commercial ramp is a gradual growth story rather than a binary catalyst.
Pombiliti is already approved and commercializing, so the next catalysts are commercial execution metrics in BioMarin's quarterly earnings reports and any potential label expansion. Watch for Q3 2026 Pombiliti+Opfolda revenue contribution when BioMarin reports earnings on November 2, 2026 (today), and monitor Sanofi's Nexviazyme competitive moves including its potential infantile-onset Pompe label expansion.
Price Chart
Executive Summary
Pombiliti (cipaglucosidase alfa) is an FDA-approved enzyme replacement therapy for late-onset Pompe disease, used in combination with Opfolda (miglustat). Originally developed by Amicus Therapeutics, it was acquired by BioMarin Pharmaceutical (BMRN) in a $4.8 billion deal that closed in April 2026. The drug generated $112.5 million in 2025 sales (60% YoY growth) and is now part of BioMarin's commercial portfolio alongside Voxzogo and Galafold. Five-year Phase 3 extension data presented in October 2026 showed durable efficacy. Pombiliti faces competition from Sanofi's Nexviazyme, which has a broader label covering patients aged 1 year and older.
How It Works
Pombiliti is an enzyme replacement therapy that replaces the missing or deficient acid alpha-glucosidase (GAA) enzyme in patients with Pompe disease. It is administered intravenously and must be taken together with Opfolda (miglustat), an oral enzyme stabilizer that prevents the breakdown of the infused enzyme in the bloodstream, allowing more of it to reach the target tissues.
Trial Status
Pombiliti was FDA-approved on September 28, 2023 based on the pivotal Phase 3 PROPEL trial. Five-year open-label extension data from PROPEL were presented at the World Muscle Society congress in October 2026, showing durable efficacy and no new safety signals in 62 enzyme-experienced adult patients with late-onset Pompe disease.
The Two-Sided Case
Upcoming Catalysts
- Quarterly revenue and commercial execution updates in BioMarin earnings reports
- Potential label expansion to broader Pompe patient populations
- Sanofi Nexviazyme competitive developments including infantile-onset Pompe label expansion
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report